Fig. 1

A Traditional free drug delivery approaches limit efficacy of combinatorial strategies due to challenges associated with varying pharmacokinetics that may result in loss of synergy. Here, the short half-life of Drug A suggests the combination with Drug B and Drug C will not synergize and ameliorate all of the challenges associated with this combination therapy. B The co-delivery of different drugs in a nano-cocktail would result in better efficacy than co-delivery of the free drugs